![](https://partners4access.com/wp-content/uploads/2023/05/chinashadow-768x468.jpg)
Is the Chinese market for pharmaceuticals going to overtake a stagnant Europe?
Written by: James Lee, Analyst Contact: [email protected] China, with 1.4 billion people, holds promise as a market for pharmaceutical companies due to its major overhaul of
![](https://partners4access.com/wp-content/uploads/2023/04/HEv2-768x468.jpg)
Hospital Exemption; still a big risk for pharma
Written by: Angeliki Meletsi; Analyst Contact: [email protected] The European Commission proposals on the EU pharmaceutical legislation revision, announced in April 2023, have not included any
![](https://partners4access.com/wp-content/uploads/2023/04/FDAacc-768x542.png)
Accelerated approval and accelerated withdrawal – will the new clinical trial guidance bring US closer to Europe?
Written by: Srishti Gupta, PhD; Senior Consultant Contact: [email protected] In March 2023, the Food and Drug Administration (FDA) published, a first of its kind, draft
![](https://partners4access.com/wp-content/uploads/2023/02/AdobeStock_87359598-2-768x512.jpeg)
Orphan Drug market, how is Italy doing? The latest OSSFOR Booklet paints a favourable picture for the Italian landscape.
By Marco Sancandi, PhD; Analyst On the 31st of January 2023, the 6th joint report from the Orphan Drugs Observatory and the Italian Society of
![](https://partners4access.com/wp-content/uploads/2023/02/MHRAv4-768x452.jpg)
New UK Regulation to Spark Major Changes in the CAR-T Landscape
By Fisentzos Stylianou, PhD; Senior Analyst The UK will be the first country to introduce a regulatory framework for innovative medicines manufactured at the point
![](https://partners4access.com/wp-content/uploads/2022/03/EUHTAv2-768x407.png)
Official countdown for the implementation of the Joint European Health Technology Assessment (EUnetHTA) begins!
Written by Priyanka Kiritharan, Analyst Contact: [email protected] Taking effect from January 2025, all advanced therapeutic medicines (ATMPs) and oncology drugs will be mandated to undergo
![](https://partners4access.com/wp-content/uploads/2022/12/Picture2-768x461.jpg)
Is the G-BA becoming more lenient towards surrogate endpoints?
By Fisentzos Stylianou, PhD; Senior Analyst Contact: [email protected] “I can say on behalf of the G-BA that it is possible that we will recognise some
![](https://partners4access.com/wp-content/uploads/2022/09/NICElinkedinV4-768x456.png)
Is the Innovative Medicines Fund a risk too great for small pharmaceutical companies?
By Fisentzos Stylianou, PhD Contact: [email protected] NICE’s launches a real-world evidence framework Closing knowledge gaps and advancing patient access to innovations are major aims of the
![](https://partners4access.com/wp-content/uploads/2022/09/french-flag-g8f9865716_1280-768x512.png)
HAS Changes its Criteria for Pharmacoeconomic Evaluation
By Priyanka Kiritharan, Analyst Email: [email protected] Last month, France’s HTA body; Haute Autorite De Sante (HAS) changed its criteria that triggers the cost-effectiveness evaluation of products